Document is current
Any future updates will be listed below
-
Authors
Izumi, Yukitoshi
Reiersen, Angela M. https://orcid.org/0000-0003-3203-4590
Lenze, Eric J.
Mennerick, Steven J. https://orcid.org/0000-0003-0868-0664
Zorumski, Charles F. https://orcid.org/0000-0002-9704-5154
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH101874, MH122379, MH101874, MH123748, MH122379)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
WUSTL | Washington University School of Medicine in St. Louis | Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis
Bantly Foundaton is a private foundation.
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 17 November 2022
Revised: 26 January 2023
Accepted: 30 January 2023
First Online: 3 February 2023
Competing interests
: CFZ serves on the Scientific Advisory Board of Sage Therapeutics and has equity in Sage Therapeutics. Sage Therapeutics did not fund this research. AMR and EJL have a patent pending on methods of treating COVID-19, including fluvoxamine. The remaining authors declare no competing interests.
